Drug intelligence / Profile preview

slow sodium

Development stage: Unknown
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Slow Sodium is a pharmaceutical formulation of sodium, typically administered as tablets, designed to provide a controlled increase in sodium intake. It has been investigated in clinical trials to study the effects of sodium loading on various physiological pathways, including the L-arginine-nitric oxide pathway and blood vessel function in patients with chronic kidney disease. It has also been used to assess the impact of dietary sodium reduction on circulating short-chain fatty acids, blood pressure, and cardiovascular phenotypes in individuals with hypertension.

Beyond the preview

Go deeper on slow sodium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on slow sodium.

Explore the full profile